Evaluation of Anticancer Activity of 1,3-Oxazol-4-ylphosphonium Salts in Vitro

Mykhailo Brusnakov, Olexandr Golovchenko, Yevheniia Velihina,* Oleksandr Liavynets, Victor Zhirnov, and Volodymyr Brovarets*
Table of Contents

I. \textsuperscript{1}H, \textsuperscript{13}C and \textsuperscript{31}P NMR, IR and Mass Spectra................................................................. S2-S69

II. Table S1. Data from an one-dose (10\textsuperscript{5} µM) antitumor screening of synthesized compounds against human tumor cell lines NCI-60, whose growth was inhibited by more than 50%............................................................ S70-S73

III. Table S2. Values of the anticancer activity parameters (GI\textsubscript{50}, TGI and LC\textsubscript{50}, µM) for the most active compounds against the NCI 60 human cancer cell lines (five-dose assay).................................................................................................................. S74-S76

IV. Table S3. Selectivity indices of compounds 1, 4 and 9......................................................... S77
Figure S1. $^1$H NMR (400 MHz, 294 K, DMSO-$d_6$) spectrum of compound (1).
Figure S2. $^{13}$C NMR (151 MHz, 298 K, DMSO-$d_6$) spectrum of compound (1).
Figure S3. $^{31}$P NMR (102 MHz, 294 K, DMSO-$d_6$) spectrum of compound (1).
Figure S4. IR spectrum of compound (1).
**Figure S5.** LCMS spectrum of compound (1).
Figure S6. $^1$H NMR (400 MHz, 294 K, DMSO-$d_6$) spectrum of compound (2).
Figure S7. $^{13}$C NMR (151 MHz, 298 K, DMSO-$d_6$) spectrum of compound (2).
Figure S8. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (2).
Figure S9. IR spectrum of compound (2).
Figure S10. LCMS spectrum of compound (2).
Figure S11. $^1$H NMR (400 MHz, 294 K, DMSO-$d_6$) spectrum of compound (3).
Figure S12. $^{13}$C NMR (126 MHz, 298 K, DMSO-$d_6$) spectrum of compound (3).
**Figure S13.** $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (3).
Figure S14. IR spectrum of compound (3).
Figure S15. LCMS spectrum of compound (3).
Figure S16. $^1$H NMR (400 MHz, 294 K, DMSO-$d_6$) spectrum of compound (4).
Figure S17. $^{13}$C NMR (126 MHz, 298 K, DMSO-$d_6$) spectrum of compound (4).
Figure S18. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (4).
Figure S19. LCMS spectrum of compound (4).
Figure S20. $^1$H NMR (400 MHz, 294 K, DMSO-$d_6$) spectrum of compound (5).
Figure S21. $^{13}$C NMR (126 MHz, 298 K, DMSO-$d_6$) spectrum of compound (5).
Figure S22. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (5).
Figure S23. IR spectrum of compound (5).
Figure S24. LCMS spectrum of compound (S).
Figure S25. $^1$H NMR (400 MHz, 298 K, DMSO-$d_6$) spectrum of compound (6).
Figure S26. $^{13}$C NMR (126 MHz, 683 K, DMSO-$d_6$) spectrum of compound (6).
Figure S27. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (6).
Figure S28. IR spectrum of compound (6).
Figure S29. LCMS spectrum of compound (6).
Figure S30. $^1$H NMR (400 MHz, 294 K, DMSO-$d_6$) spectrum of compound (7).
Figure S31. $^{13}$C NMR (151 MHz, 298 K, DMSO-$d_6$) spectrum of compound (7).
Figure S32. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (7).

S33
Figure S33. IR spectrum of compound (7).
Figure S34. LCMS spectrum of compound (7).
Figure S35. $^1$H NMR (400 MHz, 298 K, DMSO-$d_6$) spectrum of compound (8).
Figure S36. $^{13}$C NMR (127 MHz, 298 K, DMSO-$d_6$) spectrum of compound (8).
Figure S37. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (8).
Figure S38. LCMS spectrum of compound (8).
Figure S39. $^1$H NMR (400 MHz, 298 K, DMSO-$d_6$) spectrum of compound (9).
Figure S40. $^{13}$C NMR (126 MHz, 683 K, DMSO-$d_6$) spectrum of compound (9).
Figure S41. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (9).
Figure S42. IR spectrum of compound (9).
**Figure S43.** LCMS spectrum of compound (9).
Figure S44. $^1$H NMR (400 MHz, 298 K, DMSO-$d_6$) spectrum of compound (10).
Figure S45. $^{13}$C NMR (126 MHz, 683 K, DMSO-$d_6$) spectrum of compound (10).
Figure S46. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (10).
Figure S47. IR spectrum of compound (10).
Figure S48. LCMS spectrum of compound (10).
Figure S49. $^1$H NMR (400 MHz, 298 K, DMSO-$d_6$) spectrum of compound (11).
Figure S50. $^{13}$C NMR (126 MHz, 683 K, DMSO-$d_6$) spectrum of compound (11).
Figure S51. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (11).
Figure S52. IR spectrum of compound (11).
Figure S53. LCMS spectrum of compound (11).
Figure S54. $^1$H NMR (400 MHz, 298 K, DMSO-$d_6$) spectrum of compound (12).
Figure S55. $^{13}$C NMR (126 MHz, 683 K, DMSO-$d_6$) spectrum of compound (12).
Figure S56. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (12).
Figure S57. IR spectrum of compound (12).
Figure S58. LCMS spectrum of compound (12).
Figure S59. $^1$H NMR (400 MHz, 298 K, DMSO-$d_6$) spectrum of compound (13).
Figure S60. $^{13}$C NMR (126 MHz, 683 K, DMSO-$d_6$) spectrum of compound (13).
Figure S61. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (13).
Figure S62. IR spectrum of compound (13).
Figure S63. LCMS spectrum of compound (13).
Figure S64. $^1$H NMR (400 MHz, 298 K, DMSO-$d_6$) spectrum of compound (14).
Figure S65. $^{13}$C NMR (126 MHz, 683 K, DMSO-$d_6$) spectrum of compound (14).
Figure S66. $^{31}$P NMR (162 MHz, 294 K, DMSO-$d_6$) spectrum of compound (14).
Figure S67. IR spectrum of compound (14).
Figure S68. LCMS spectrum of compound (14).
Table S1. Data from an one-dose ($10^5$ μM) antitumor screening of synthesized compounds against human tumor cell lines NCI-60, whose growth was inhibited by more than 50%.

| Compound | Leukemia | Non-Small Cell Lung cancer | Colon cancer | CNS cancer | Melanoma cancer | Ovarian cancer | Renal cancer | Prostate Cancer | Breast cancer |
|----------|----------|-----------------------------|--------------|-----------|----------------|----------------|--------------|----------------|---------------|
| 1 | CCRF-CEM (94) | | | | | | | | |
| | HL-60(TB) (133) | | | | | | | | |
| | K-562 (99) | | | | | | | | |
| | MOLT-4 (102) | | | | | | | | |
| | RPMI-8226 (72) | | | | | | | | |
| | SR (91) | | | | | | | | |
| 2 | CCRF-CEM (87) | | | | | | | | |
| | HL-60(TB) (112) | | | | | | | | |
| | K-562 (90) | | | | | | | | |
| | MOLT-4 (92) | | | | | | | | |
| | RPMI-8226 (129) | | | | | | | | |
| | NCI-H226 | | | | | | | | |
| | NCI-H322M | | | | | | | | |
| | NCI-H460 | | | | | | | | |
| | NCI-H522 | | | | | | | | |
| 4 | CCRF-CEM (100) | | | | | | | | |
| | HL-60(TB) (148) | | | | | | | | |
| | K-562 (99) | | | | | | | | |
| | MOLT-4 (109) | | | | | | | | |
| | RPMI-8226 (150) | | | | | | | | |

S70
| Cell Line | Source | Tumor Type | Growth Medium |
|-----------|--------|------------|---------------|
| CCRF-CEM | (92)   | Majority   | RPMI-8226     |
| HL-60(TB)| (128)  | Majority   | RPMI-8226     |
| K-562    | (95)   | Majority   | RPMI-8226     |
| MOLT-4   | (108)  | Majority   | RPMI-8226     |
| SR       | (94)   | Majority   | RPMI-8226     |
| CCRF-CEM | (79)   | Majority   | RPMI-8226     |
| HL-60(TB)| (103)  | Majority   | RPMI-8226     |
| K-562    | (84)   | Majority   | RPMI-8226     |
| MOLT-4   | (71)   | Majority   | RPMI-8226     |
| SR       | (80)   | Majority   | RPMI-8226     |
| CCRF-CEM | (89)   | Majority   | RPMI-8226     |
| HL-60(TB)| (135)  | Majority   | RPMI-8226     |
| K-562    | (93)   | Majority   | RPMI-8226     |
| MOLT-4   | (99)   | Majority   | RPMI-8226     |
| SR       | (119)  | Majority   | RPMI-8226     |
|    | SR (99) | NCI-H23 (112) | NCI-H322M (106) | NCI-H460 (99) | NCI-H522 (120) | KM12 (116) | SW-620 (89) | SNB-75 (93) | U251 (85) | SK-MEL-28 (70) | SK-MEL-5 (192) | UACC-257 (92) | UACC-62 (100) | OVCAR-8 (92) | SK-OV-3 (116) | SN12C (97) | TK-10 (76) | UO-31 (131) | MDA-MB-468 (138) |
|----|---------|--------------|-----------------|---------------|---------------|------------|----------|-----------|---------|---------------|---------------|----------------|----------------|------------|--------------|---------|-----------|----------|----------------|
| 9  | CCRF-CEM (102) | H460 (TB) (145) | K-562 (95) | MOLT-4 (126) | RPMI-8226 (138) | SR (118) | A549/ATCC (92) | EKVX (93) | HOP-62 (90) | HOP-92 (109) | NCI-H226 (84) | NCI-H23 (117) | NCI-H322M (90) | NCI-H460 (140) | NCI-H522 (139) | COLO 205 (141) | HCC-2998 (98) | HCT-116 (98) | HCT-15 (99) | HT29 (99) | KM12 (153) | SW-620 (105) | SF-268 (99) | SF-295 (90) | SF-539 (105) | SNB-19 (86) | SNB-75 (124) | U251 (87) | LOX IMVI (169) | MALME-3M (141) | M14 (93) | MDA-MB-435 (130) | SK-MEL-2 (136) | SK-MEL-28 (83) | SK-MEL-5 (198) | UACC-257 (99) | UACC-62 (138) | IGROV1 (174) | OVCAR-3 (103) | OVCAR-4 (103) | OVCAR-5 (92) | OVCAR-8 (95) | NC1/ADR-RES (98) | SK-OV-3 (103) | 786-0 (96) | A498 (141) | ACHN - 6.75 | Caki-1 (123) | RXF 393 (119) | SN12C (96) | TK-10 (77) | UO-31 (122) | PC-3 (96) | DU-145 (88) | MCF7 (124) | MDA-MB-231/ATCC (113) | HS 578T (108) | BT-549 (131) | T-47D 1.57 | MDA-MB-468 (137) |
| 10 | HL-60(TB) (53) | K-562 (69) | RPMI-8226 (94) | SR (69) | NCI-H23 (70) | NCI-H460 (63) | COLO 205 (93) | HCC-2998 (57) | HCT-116 (67) | KM12 (77) | SNB-19 (55) | U251 (58) | LOX IMVI (71) | MDA-MB-435 (59) | SK-MEL-5 (109) | UACC-257 (79) | UACC-62 (53) | OVCAR-3 (63) | OVCAR-4 (65) | -- | -- | MCF7 (77) | BT-549 (57) | T-47D (91) | MDA-MB-468 (104) |
| 11 | CCRF-CEM (107) | HL-60(TB) (114) | K-562 (96) | MOLT-4 (103) | RPMI-8226 (128) | SR (111) | A549/ATCC (73) | EKVX (77) | HOP-62 (82) | HOP-92 (108) | NCI-H226 (53) | NCI-H23 (85) | NCI-H460 (95) | COLO 205 (138) | HCC-2998 (62) | HCT-116 (169) | HCT-15 (96) | HT29 (100) | KM12 (81) | SW-620 (170) | SF-268 (55) | SF-539 (166) | SNB-75 (111) | U251 (97) | MALME-3M (101) | M14 (81) | MDA-MB-435 (103) | SK-MEL-2 (78) | SK-MEL-28 (75) | SK-MEL-5 (51) | UACC-257 (96) | IGROV1 (74) | OVCAR-3 (100) | OVCAR-4 (76) | OVCAR-5 (75) | OVCAR-8 (92) | 786-0 (119) | A498 (101) | ACHN (113) | Caki-1 (94) | RXF 393 (129) | SN12C (96) | TK-10 (97) | PC-3 (89) | DU-145 (75) | MCF7 (87) | MDA-MB-231/ATCC (97) | HS 578T (110) | BT-549 (91) | T-47D (81) | MDA-MB-468 (121) |
| 12 | NCI-H522 (96) | UACC-62 (74) | UO-31 (85) |
|----|---------------|---------------|------------|
| CCRF-CEM (62) | AS49/ATCC (77) | COLO 205 (107) | LOX IMVI (74) |
| HL-60(TB) (93) | EKVX (74) | HCC-2998 (71) | MALME-3M (69) |
| K-562 (80) | HOP-62 (79) | HCT-116 (86) | M14 (67) |
| MOLT-4 (62) | HOP-92 (75) | HT29 (83) | MDA-MB-435 (75) |
| RPMI-8226 (95) | NCI-H23 (79) | KM12 (92) | SK-MEL-2 (50) |
| SR (64) | NCI-H460 (83) | SW-620 (66) | SK-MEL-5 (98) |
| | NCI-H522 (75) | | UACC-257 (88) |
| | | | UACC-62 (71) |
| | | | IGROV1 30.31 |
| | | | SN12C 15.81 |
| | | | OVCAR-3 38.24 |
| | | | OVCAR-4 69.23 |
| | | | OVCAR-5 21.47 |
| | | | NCI/ADR-RES 97.80 |
| | | | SK-OV-3 28.04 |
| | | | A498 (81) |
| | | | SN12C (72) |
| | | | TK-10 (52) |
| | | | -- |
| | | | MCF7 (86) |
| | | | MDA-MB-231/ATCC 51 |
| | | | BT-549 (88) |
| | | | T-47D (85) |
| | | | MDA-MB-468 (120) |
Table S2. Values of the anticancer activity parameters (GI50, TGI and LC50, μM) for the most active compounds against the NCI 60 human cancer cell lines (five-dose assay).

| Cell Line        | Compound       | 1  | 2  | 4  | 5  | 8  | 9  | 11 |
|------------------|----------------|----|----|----|----|----|----|----|
|                  |                | Gl50| TGI| Lc50| Gl50| TGI| Lc50| Gl50| TGI| Lc50| Gl50| TGI| Lc50| Gl50| TGI| Lc50| Gl50| TGI| Lc50| Gl50| TGI| Lc50| Gl50| TGI| Lc50| Gl50| TGI| Lc50|
| Leukemia         |                |    |    |    |    |    |    |    |
| CCRF-CEM         |                | 0.40| 2.24| 22.9| 0.99| 85.4| >100| 0.43| 2.17| 8.74| 0.48| 9.49| >100| 0.37| 2.88| >100| 0.30| 1.61| >100| 0.61| 6.94| >100|
| HL-60(TB)        |                | 0.25| 0.61| 4.39| 0.34| 1.50| >100| 0.25| 0.73| 6.39| 0.25| 0.70| 10.9| 0.23| 0.55| nd  | 0.22| 0.54| 36.8| 1.67| 4.38| 41.2|
| K-562            |                | 0.29| 1.18| 6.63| 0.42| >100| >100| 0.31| 1.15| 4.74| 0.32| 3.58| >100| 0.22| 2.88| >100| 0.29| 1.52| >100| 0.31| 3.22| >100|
| MOLT-4           |                | 0.41| 1.83| 7.95| 2.17| 22.0| >100| 0.50| 2.03| 6.94| 0.49| 3.13| 37.9| 0.40| 1.76| nd  | 0.33| 1.18| 9.35| 1.06| 4.63| 41.4|
| RPMI-8226nd      |                | 0.21| 0.52| 3.36| 0.27| 1.43| >100| 0.18| 0.55| 8.65| 0.20| 0.69| 77.7| 0.17| 0.55| >100| nd  | nd  | nd  | nd  | nd  |
| SR               |                | 0.39| 1.80| >100| 0.60| 26.8| >100| 0.36| 1.71| 13.6| 0.41| 5.64| >100| 0.38| 24.2| >100| nd  | nd  | nd  | nd  | nd  |
| Non-Small Cell Lung Cancer |       |    |    |    |    |    |    |    |
| A549/ATCC        |                | 0.61| 2.12| 5.50| 2.49| 46.4| >100| 1.31| 3.13| 7.49| 0.43| 11.8| 61.0| 0.31| 10.8| 52.6| 0.31| 1.24| 4.06| 2.00| 5.14| 17.3|
| EKVX             |                | 0.37| 1.69| 5.18| 1.84| 34.9| >100| 0.94| 2.37| 5.72| 0.97| 8.50| 47.6| 0.35| 4.37| 30.9| 0.27| 1.20| 4.47| 1.21| 2.98| 7.32|
| HOP-62           |                | 1.26| 3.05| 7.40| 1.82| 14.8| >100| 1.35| 3.45| nd  | 0.59| 5.61| 41.0| 0.30| 2.52| 55.2| 0.44| 1.79| nd  | 1.47| 4.56| 28.1|
| HOP-92           |                | 0.18| 0.81| 3.09| 0.38| 3.08| 35.0| 0.12| 0.92| 3.73| 0.32| 2.24| 24.2| 0.13| 0.52| 10.9| 0.14| 0.61| 3.85| 1.43| 3.13| 6.81|
| NCI-H226         |                | nd  | nd  | nd  | nd  | nd  | nd  | 1.33| 3.22| nd  | nd  | nd  | nd  | 0.41| 1.90| nd  | nd  | nd  | nd  | nd  | nd  | nd  |
| NCI-H23          |                | 0.39| 1.53| 5.41| 1.91| 6.54| 94.9| 0.36| 1.46| 5.00| 0.45| 5.80| 37.5| 0.29| 1.37| 35.6| 0.31| 1.10| 6.25| 1.68| 3.50| 7.31|
| NCI-H322M        |                | 1.13| 2.41| 5.14| 2.86| 13.1| >100| 1.01| 2.18| 4.74| 1.12| 7.87| 31.6| 0.32| 2.72| 23.5| 0.43| 1.70| 4.68| 3.18| 12.6| 35.4|
| NCI-H460         |                | 0.46| 1.62| 4.38| 2.02| 11.1| 85.3| 0.47| 1.69| 4.68| 0.38| 10.2| 37.5| 0.29| 1.05| 8.69| 0.31| 1.11| 4.30| 1.64| 3.43| 7.20|
| NCI-H522         |                | 0.31| 1.35| 5.01| 0.47| 3.93| 82.1| 0.24| 1.23| 6.61| 0.37| 4.94| 49.2| 0.27| 1.29| 8.68| 0.15| 0.38| 0.97| 1.60| 3.67| 8.39|
| Colon Cancer     |                |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
| COLO 205         |                | nd  | nd  | nd  | nd  | nd  | nd  | 0.74| 2.74| nd  | nd  | nd  | nd  | 0.39| 2.72| 21.7| 0.24| 0.69| nd  | 1.71| 4.28| >100|
| HCC-2998         |                | 0.76| 2.03| 4.63| 0.68| 10.9| 35.6| 0.59| 1.97| 4.91| 0.42| 4.07| 26.2| 0.31| 10.1| 40.0| 0.40| 1.64| 4.84| 1.45| 3.01| 6.24|
| HCT-116          |                | 0.35| 1.20| 3.52| 0.82| 8.40| 8.22| 0.35| 1.38| nd  | 0.35| 10.7| 40.8| 1.12| 10.4| 40.0| 0.32| 1.21| nd  | 1.37| 2.75| 5.51|
| HCT-15           |                | 0.37| 1.45| 4.64| 7.85| 6.74| >100| 0.50| 1.87| 4.97| 2.81| 11.0| 39.6| 0.29| 3.78| 50.8| 0.29| 1.22| 4.74| 1.44| 3.23| 7.25|
| HT29             |                | 0.31| 1.14| 6.17| 0.53| 11.1| >100| 0.36| 1.64| >100| 0.35| 10.7| 86.8| 0.29| 1.08| 3.79| 0.29| 1.15| 5.90| 1.69| 4.17| 11.9|
| Cell Line | SK-12 | SK-N-CI | OVCAR-3 | OVCAR-5 | OVCAR-7 | NCI-ADR-RES |
|-----------|-------|---------|---------|---------|---------|-------------|
| CNS Cancer |       |         |         |         |         |             |
| SF-268    | 1.13  | 2.53    | 5.69    | 0.59    | 11.4    | 52.2        |
| SF-295    | 1.15  | 2.41    | 5.06    | 1.98    | 5.64    | 41.8        |
| SF-539    | 1.55  | 2.93    | 5.52    | 1.35    | 10.1    | 37.6        |
| SNB-19    | 0.66  | 1.95    | 4.64    | 0.42    | 14.8    | >100        |
| SNB-75    | 1.18  | 2.46    | 5.10    | 0.28    | 1.57    | 10.8        |
| U251      | 0.23  | 1.08    | 3.42    | 0.49    | 11.6    | 80.3        |
| Melanoma  |       |         |         |         |         |             |
| LOX IMVI  | 0.61  | 1.89    | 4.44    | 1.13    | 2.74    | 6.63        |
| MALME-3M  | 0.28  | 0.99    | 3.81    | 0.44    | 4.11    | 29.6        |
| M14       | 0.41  | 1.59    | 4.20    | 1.27    | 10.1    | 47.7        |
| MDA-MB-435| 0.41  | 1.48    | 3.89    | 0.40    | 3.38    | 31.9        |
| SK-MEL-2  | 0.33  | 1.24    | 4.58    | 0.89    | 3.83    | 25.5        |
| SK-MEL-28 | 1.01  | 2.25    | 4.99    | 0.57    | 12.4    | 41.4        |
| SK-MEL-5  | 0.28  | 0.93    | 3.15    | 0.53    | 1.78    | 4.45        |
| UACC-257  | 0.41  | 1.64    | 4.63    | 0.37    | 2.64    | >100        |
| UACC-62   | 0.46  | 1.69    | 4.43    | 0.48    | 2.93    | 22.4        |
| Ovarian Cancer |       |         |         |         |         |             |
| IGROV1    | 0.69  | 2.07    | 5.09    | 0.44    | 5.45    | 41.1        |
| OVCAR-3   | 0.29  | 0.87    | 3.14    | 0.45    | 3.50    | >100        |
| OVCAR-4   | 0.34  | 1.24    | 4.21    | 0.39    | 8.09    | >100        |
| OVCAR-5   | 1.36  | 2.96    | 6.42    | 2.14    | 10.6    | >100        |
| OVCAR-8   | 0.75  | 2.26    | 5.86    | 8.04    | 8.37    | >100        |
| NCI/ADR-RES| 1.29  | 2.72    | 5.73    | 58.4    | >100    | >100        |
| SK-OV-3   | nd    | nd      | nd      | nd      | nd      | nd          |
|    | 786-O | A498 | ACHN | CAKI-1 | RXF 393 | SN12C | TK-10 | UO-31 | Prostate Cancer | Breast Cancer |
|----|-------|------|------|--------|---------|-------|-------|-------|-----------------|---------------|
|    | 0.79  | 0.63 | 0.69 | 1.10   | 0.65    | 0.67  | 1.10  | 0.32  | 0.41            | 0.30          |
|    | 2.05  | 2.10 | 1.93 | 2.39   | 2.14    | 2.05  | 2.50  | 1.40  | 1.58            | 1.15          |
|    | 4.55  | 4.77 | 4.40 | 5.21   | 5.41    | 5.06  | 5.64  | 5.14  | 5.14            | 4.22          |
|    | 3.26  | nd   | 3.06 | 2.20   | 1.16    | 0.69  | 0.79  | 0.45  | 5.14            | 0.33          |
|    | 21.6  | nd   | 13.6 | 6.28   | 5.42    | 8.05  | 11.8  | 3.13  | 6.43            | 3.62          |
|    | >100  | nd   | >100 | >100   | 27.5    | 36.6  | 55.5  | >100  | >100            | >100          |
|    | 1.24  | 1.05 | 2.35 | 1.23   | 0.81    | 0.45  | 1.28  | 0.45  | 0.49            | 0.33          |
|    | 2.62  | 2.23 | 2.35 | 2.63   | 2.22    | 1.67  | 2.63  | 1.77  | 2.01            | 0.37          |
|    | 5.53  | 4.72 | 5.19 | 5.40   | 5.41    | 4.14  | 6.06  | 4.21  | 5.77            | 4.74          |
|    | 1.87  | 2.12 | 1.50 | 10.4   | 0.60    | 0.33  | 1.46  | 1.82  | 0.33            | 0.43          |
|    | 12.5  | 7.06 | 48.4 | 37.3   | 3.21    | 1.68  | 10.0  | 5.06  | 3.55            | 3.62          |
|    | 40.7  | 26.0 | >100 | 37.6   | 17.5    | 31.1  | 40.0  | 18.2  | >100            | >100          |
|    | 0.37  | 0.35 | 1.05 | 0.27   | 0.31    | 0.29  | 0.31  | 0.31  | 0.27            | 0.27          |
|    | 2.80  | 1.37 | 4.36 | 1.29   | 1.47    | 1.27  | 1.43  | 1.47  | 1.29            | 1.29          |
|    | 23.1  | 1.08 | 9.36 | 34.8   | 0.63    | 1.24  | 1.37  | 26.7  | 34.8            | 34.8          |
|    | 0.39  | 3.44 | 31.2 | 0.30   | 0.30    | 1.24  | 0.43  | 0.43  | 0.30            | 0.30          |
|    | 1.69  | 1.08 | 0.27 | 1.29   | 0.27    | 1.37  | 1.53  | 1.53  | 1.37            | 1.37          |
|    | nd    | 3.70 | 3.94 | 30.9   | 1.08    | 1.24  | 1.53  | 1.53  | 1.37            | 1.37          |
|    | 1.46  | 1.70 | 31.9 | nd     | 0.26    | 1.44  | 1.46  | 1.46  | 1.46            | 1.46          |
|    | 2.85  | 5.57 | 31.1 | 21.7   | 0.26    | 2.85  | 2.92  | 2.92  | 2.92            | 2.92          |
|    | 5.57  |      | 21.7 | 17.4   | 0.26    | 2.92  | 2.92  | 2.92  | 2.92            | 2.92          |

Prostate Cancer

|    | PC-3  | DU-145 |
|----|-------|--------|
|    | 0.41  | 1.03   |
|    | 1.58  | 5.64   |
|    | 5.14  | 0.79   |
|    | 0.45  | 11.8   |
|    | 6.43  | 55.5   |
|    | >100  | >100   |
|    | 0.49  | 0.47   |
|    | 2.01  | 10.4   |
|    | 5.77  | 37.3   |
|    | 0.33  | 0.35   |
|    | 3.55  | 26.7   |
|    | 37.6  | 43.8   |
|    | 0.27  | 1.35   |
|    | 1.29  | 34.8   |

Breast Cancer

|    | MCF7  | MDA-MB-231/ATCC | Hs 578T | BT-549 | T-47D | MDA-MB-468 |
|----|-------|-----------------|---------|--------|-------|------------|
|    | 0.30  | 0.53            | 1.14    | 1.15   | 0.27  | 0.26       |
|    | 1.15  | 1.82            | 3.49    | 2.38   | 1.38  | 0.77       |
|    | 4.22  | 4.61            | 13.40   | 4.93   | 8.36  | 3.80       |
|    | 0.33  | 0.71            | 1.09    | 0.35   | 0.37  | 0.25       |
|    | 3.62  | 6.16            | 8.27    | 3.85   | 15.8  | 0.87       |
|    | >100  | 67.6            | >100    | 31.2   | >100  | 24.2       |
|    | 0.34  | 0.44            | 1.43    | 1.61   | 0.44  | 0.22       |
|    | 1.50  | 2.04            | 3.58    | 1.31   | 2.40  | 0.27       |
|    | 0.31  | 0.47            | 8.95    | 5.99   | 5.94  | 0.25       |
|    | 1.32  | 2.40            | >100    | 4.11   | >100  | 3.41       |
|    | 33.7  | 27.1            | 1.04    | 32.3   | 0.27  | 20.1       |
|    | 0.25  | 0.29            | 0.46    | 0.27   | 0.27  | 0.21       |
|    | 1.39  | 1.29            | 5.94    | 3.27   | 1.88  | 0.82       |
|    | 41.6  | 5.78            | 27.1    | 29.9   | 0.35  | 8.82       |
|    | 0.29  | 1.20            | 1.20    | 0.32   | 1.88  | 0.23       |
|    | 1.11  | 1.25            | 0.31    | 0.32   | 2.99  | 4.14       |
|    | 5.23  | 1.25            | 1.31    | >100   | 1.22  | 1.03       |
|    | 1.52  | 5.32            | 1.37    | 2.93   | 1.99  | 2.61       |
|    | 3.83  | >100            | 1.37    | 5.64   | 5.57  | 6.61       |

Average values

|    | 0.62  | 0.53  | 1.29  | 9.55  | 63.10 | 0.77  | 2.12  | 5.68  | 0.60  | 6.31  | 38.02 | 0.31  | 2.29  | 22.91 | 0.34  | 1.34  | 4.90  | 1.48  | 3.72  | 11.48 |

S76
Table S3. Selectivity indices of compounds 1, 4 and 9.

| Subpanel       | Compound | 1 | 4 | 9 |
|----------------|----------|---|---|---|
|                | GI<sub>50</sub> | TGI | LC<sub>50</sub> | GI<sub>50</sub> | TGI | LC<sub>50</sub> | GI<sub>50</sub> | TGI | LC<sub>50</sub> |
| Leukemia       | 1.9 | 1.3 | 0.6<sup>1</sup> | 1.0 | 1.0 | 1.4 | 1.2 | 1.1 | NC          |
| NSLC           | 1.1 | 1.0 | 1.1 | 1.0 | 1.0 | 1.1<sup>2</sup> | 1.1 | 1.1 | 1.2<sup>2</sup> |
| Colon Cancer   | 1.4 | 1.2 | 1.2 | 1.5 | 1.1 | 1.2<sup>4</sup> | 1.1 | 1.1 | 1.0<sup>5</sup> |
| CNS Cancer     | 0.6 | 0.8 | 1.1 | 0.7 | 0.9 | 1.1 | 1.1 | 1.0 | 1.2         |
| Melanoma       | 1.3 | 1.2 | 1.3 | 1.1 | 1.0 | 1.1<sup>6</sup> | 0.6 | 0.9 | 1.2         |
| Ovarian Cancer | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 | 1.2<sup>7</sup> | 0.9 | 0.8 | 2.4<sup>8</sup> |
| Renal Cancer   | 0.8 | 0.9 | 1.1 | 0.8 | 0.9 | 1.1 | 1.1 | 1.0 | 1.4<sup>9</sup> |
| Prostate Cancer| 0.9 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 0.9 | 0.9 | 0.9         |
| Breast Cancer  | 1.0 | 1.0 | 0.8 | 1.0 | 1.0 | 0.9<sup>10</sup> | 1.2 | 1.1 | 1.1<sup>11</sup> |

NC – not calculated (not enough data);

<sup>1</sup> Except for SR line (LC<sub>50</sub> > 100);
<sup>2</sup> Except for HOP-62 and NCI-H226 lines (NT);
<sup>3</sup> Except for lines HOP-62 and NCI-H226 (NT);
<sup>4</sup> Except for lines COLO 205, HCT-116 (NT) and HT29 (LC<sub>50</sub> > 100);
<sup>5</sup> Except for lines COLO 205 and HCT-116 (NT);
<sup>6</sup> Except for M14 line (NT);
<sup>7</sup> Except for OVCAR-8 line (LC<sub>50</sub> > 100);
<sup>8</sup> Except for lines IGROV1 and OVCAR-3 (NT);
<sup>9</sup> Except for 786-0 line (NT);
<sup>10</sup> Except for T-47D line (NT);
<sup>11</sup> Except for lines HS 578T (LC<sub>50</sub> > 100) and T-47D (NT);

NT - not tested.